Clinical Trial Update: ARX788 in Breast Cancer With Low Expression of HER2 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ARX788 in breast cancer with low expression of HER2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer with Low Expression of HER2

Drugs mentioned

• ARX788

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer With Low Expression of HER2 | Phase 2 | Status: UNKNOWN